Capricor Therapeutics filed its third-quarter 2026 earnings 8-K on November 10, just twelve days before the FDA’s November 22 PDUFA date for deramiocel, its cell therapy candidate for Duchenne muscular dystrophy. The timing means the quarterly financial picture lands almost simultaneously with the most consequential regulatory decision in the company’s history, compressing the window in which investors and trial stakeholders must absorb both.
The 8-K itself is a bare procedural filing: it references a press release (Exhibit 99.1) announcing Q3 results and a corporate update, but does not reproduce the financial figures. What the filing does confirm is that CEO Linda Marbán signed off on November 10, putting the company’s official posture on record just before the FDA acts. The PDUFA date for deramiocel is November 22, 2026.
Deramiocel carries Regenerative Medicine Advanced Therapy (RMAT) designation, granted in February 2018, which comes with certain FDA collaboration benefits. Deramiocel is a cell therapy candidate for Duchenne muscular dystrophy. Whether the FDA views the data package as sufficient for approval on November 22 is what actually matters here, and the Q3 filing adds no new information on that question.
The number to watch after November 22 is not approval itself but the labeled indication: how broadly or narrowly the FDA defines the eligible patient population will determine what a commercial launch actually reaches, and that scope will not be visible until the approval letter, if one comes.
Source link: https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-20261110x8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
